DIA vs IBB
SPDR Dow Jones Industrial Average ETF vs iShares Biotechnology ETF
- • DIA has the lower expense ratio at 0.16% vs 0.44% for IBB.
- • DIA pays a higher dividend yield (1.39%).
Side-by-side metrics
| Metric | DIA | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.16% | 0.44% |
Dividend yield Trailing 12-month yield. | 1.39% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $45.14B | $11.50B |
YTD return | 10.11% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.85 | 0.60 |
P/E ratio | 20.74 | 25.48 |
Last price | $523.59 | $217.75 |
Inception | — | — |
Issuer | State Street | iShares |
DIA top holdings
| GS | The Goldman Sachs Group Inc | 10.26% |
| CAT | Caterpillar Inc | 7.14% |
| MSFT | Microsoft Corp | 5.99% |
| AMGN | Amgen Inc | 5.35% |
| V | Visa Inc Class A | 4.74% |
| UNH | UnitedHealth Group Inc | 4.67% |
| TRV | The Travelers Companies Inc | 4.55% |
| AAPL | Apple Inc | 3.95% |
| JPM | JPMorgan Chase & Co | 3.87% |
| SHW | Sherwin-Williams Co | 3.82% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About DIA
DIA (SPDR Dow Jones Industrial Average ETF) is Tracks the 30-stock Dow Jones Industrial Average. Managed by State Street, the fund carries $45.1B in assets under management, an expense ratio of 0.16%, a dividend yield of 1.39%. Its largest holding is The Goldman Sachs Group Inc (GS), which represents 10.3% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 9.9%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.